Pictet Asset Management
SNDX icon

Pictet Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Pictet Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Hold
12,356
– – ﹤0.01% 1734
2025
Q4 		$260K Hold
12,356
– – ﹤0.01% 1784
2025
Q3 		$190K Hold
12,356
– – ﹤0.01% 1893
2025
Q2 		$116K Buy
+12,356
New +$136K ﹤0.01% 1918

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Pictet Asset Management's SNDX Position: Q1 2026 in Review

Pictet Asset Management held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 12,356 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Pictet Asset Management first reported a position in SNDX in Q2 2025 and has held it in 4 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Pictet Asset Management held 12,356 shares of Syndax Pharmaceuticals worth $289K as of Q1 2026.
  • Pictet Asset Management left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1734 holding.
  • Pictet Asset Management first reported a position in Syndax Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.